Hip Arthroscopy Postoperative Opioid Demands
Randomized Control Trial Evaluating Postoperative Opioid Demands Following Hip Arthroscopy
Who can join
Ages 18 to 80 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Adult patients age 18-80 years * English speaking * Opioid naive patient (defined as not taking opioid pills within 6 weeks prior to surgery), confirmed by checking the Illinois Prescription monitoring program * Primary hip arthroscopy * Written and informed consent for study participation Exclusion Criteria: * Minors (\<18 years of age) * Opioid tolerant patients * Revision surgery * Prior infections of the operative joint * History of active malignancy within the past 5 years * Chronic pain conditions including low back pain, chronic pain syndrome, fibromyalgia * History of alcohol or other substance use disorder * Other disease states including rheumatologic conditions, diabetes mellitus, hypo/hyperthyroidism, depression, anxiety * Grade IV chondral defects
About the study
This study will be a prospective, single-blinded, randomized controlled trial (RCT), investigating the influence of the number of opioid pills prescribed following primary hip arthroscopy. All patients who sign the consent form will be enrolled in the suited and randomized to one of the two treatment arms. The intervention group will receive 5 Norco pills, gabapentin (30 mg, once daily for 10 days following surgery), and Tylenol (1000 mg, three times daily for 10 days following surgery) while the control will receive the standard at our practice of 30 Norco pills.
What is being tested
- Control Group Regimen (other)
- Opioid reduced regimen (other)
Sponsor: Rush University Medical Center · Participants: 170 · Started: Oct 21, 2020
Contact the study team
- Carla M. Edwards · Phone: 312-563-5735
Official record on ClinicalTrials.gov — NCT04094701
Locations in the U.S.
| Illinois | Rush University Medical Center, Chicago |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.